UBS AM’s PDL BioPharma, Inc. PDLI Stock Holding History

UBS AM’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-151,896	Closed	-$478K	–	2631
2020 Q3	$478K	Hold	151,896	–	–	﹤0.01%	2166
2020 Q2	$442K	Sell	151,896 -14,433	-9%	-$45.6K	﹤0.01%	2168
2020 Q1	$469K	Buy	166,329 +7,076	+4%	+$22.8K	﹤0.01%	2001
2019 Q4	$517K	Buy	159,253 +27,919	+21%	+$81K	﹤0.01%	2223
2019 Q3	$284K	Buy	131,334 +9,953	+8%	+$26.6K	﹤0.01%	2475
2019 Q2	$381K	Hold	121,381	–	–	﹤0.01%	2324
2019 Q1	$452K	Buy	121,381 +23,561	+24%	+$79.5K	﹤0.01%	2146
2018 Q4	$284K	Sell	97,820 -1,027	-1%	-$2.82K	﹤0.01%	2233
2018 Q3	$260K	Sell	98,847 -4,266	-4%	-$10.5K	﹤0.01%	2328
2018 Q2	$241K	Hold	103,113	–	–	﹤0.01%	2394
2018 Q1	$303K	Sell	103,113 -40,052	-28%	-$109K	﹤0.01%	2209
2017 Q4	$392K	Buy	143,165 +5,293	+4%	+$16.3K	﹤0.01%	2048
2017 Q3	$467K	Hold	137,872	–	–	﹤0.01%	1969
2017 Q2	$341K	Hold	137,872	–	–	﹤0.01%	1983
2017 Q1	$313K	Buy	137,872 +54,883	+66%	+$121K	﹤0.01%	1997
2016 Q4	$176K	Sell	82,989 -32,500	-28%	-$90.7K	﹤0.01%	2156
2016 Q3	$387K	Hold	115,489	–	–	﹤0.01%	2128
2016 Q2	$362K	Hold	115,489	–	–	﹤0.01%	2133
2016 Q1	$385K	Sell	115,489 -90,734	-44%	-$283K	﹤0.01%	2072
2015 Q4	$730K	Buy	206,223 +4,200	+2%	+$17.6K	﹤0.01%	1869
2015 Q3	$1.02M	Buy	202,023 +16,182	+9%	+$92.7K	﹤0.01%	1718
2015 Q2	$1.2M	Buy	185,841 +25,076	+16%	+$168K	﹤0.01%	1620
2015 Q1	$1.13M	Buy	160,765 +45,000	+39%	+$326K	﹤0.01%	1584
2014 Q4	$893K	Buy	115,765 +5,400	+5%	+$42.7K	﹤0.01%	1637
2014 Q3	$825K	Buy	110,365 +15,500	+16%	+$144K	﹤0.01%	1627
2014 Q2	$918K	Buy	94,865 +4,700	+5%	+$41.9K	﹤0.01%	1610
2014 Q1	$749K	Buy	90,165 +49,969	+124%	+$428K	﹤0.01%	1669
2013 Q4	$339K	Sell	40,196 -1,400	-3%	-$11.8K	﹤0.01%	2043
2013 Q3	$332K	Hold	41,596	–	–	﹤0.01%	2021
2013 Q2	$321K	Buy	+41,596	New	+$324K	﹤0.01%	1956

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

UBS AM's PDLI Position: Q4 2020 in Review

UBS AM sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 151,896 shares — an estimated $478K sold.

UBS AM first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $1.2M in Q2 2015. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

UBS AM reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
UBS AM sold 151,896 PDL BioPharma, Inc. shares in Q4 2020, an estimated $478K.
UBS AM first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
UBS AM's PDL BioPharma, Inc. position peaked at $1.2M in Q2 2015.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.